ArticleExperimental and therapeutic medicine2022
Resveratrol protects against atherosclerosis by downregulating the PI3K/AKT/mTOR signaling pathway in atherosclerosis model mice.
Article in Experimental and therapeutic medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- Decoding the gut microbiota-mitochondrial-inflammasome axis in cardiovascular disease.Molecular and cellular biochemistry · 2026Review
- Effects of Amygdalin, 6-Shogaol, and Resveratrol on Inhibition of Differentiation of Monocyte-Derived M4 Macrophages: In Silico and In Vitro Studies.Bulletin of experimental biology and medicine · 2026Article
- Resveratrol Mediates Anti-Atherogenic Actions In Vitro and in LDL Receptor-Deficient Mice Fed a High-Fat Diet via Antioxidant, Anti-Inflammatory and Plaque-Stabilising Activities.Antioxidants (Basel, Switzerland) · 2026Article
- PI3K/AKT signaling pathway: new strategies for treating atherosclerosis with plant-derived compounds.Frontiers in pharmacology · 2026Review
- Natural Compounds TargetingNutrients · 2025Review
- The relevance of resveratrol in ameliorating carotid atherosclerosis through glycolysis.BMC cardiovascular disorders · 2025Article
- Traditional Chinese medicine compounds modulate signaling pathways to improve cardiac-related pathology.Frontiers in pharmacology · 2025Review
- Potential of herbal formulas and bioactive metabolites in treating atherosclerosis: targeted modulation of macrophage polarization.Frontiers in pharmacology · 2025Review
- Bioactive Flavonoids in Protecting Against Endothelial Dysfunction and Atherosclerosis.Handbook of experimental pharmacology · 2025Review
- Potential bidirectional regulatory effects of botanical drug metabolites on tumors and cardiovascular diseases based on the PI3K/Akt/mTOR pathway.Frontiers in pharmacology · 2025Review
- Article
- Nrf2-mediated ferroptosis inhibition: a novel approach for managing inflammatory diseases.Inflammopharmacology · 2024Review
- mTOR gene variant rs2295080 might be a risk factor for atherosclerosis in Iranian women with type 2 diabetes mellitus.BMC endocrine disorders · 2024Article
- Exploring Sirtuins: New Frontiers in Managing Heart Failure with Preserved Ejection Fraction.International journal of molecular sciences · 2024Review
- Cells in Atherosclerosis: Focus on Cellular Senescence from Basic Science to Clinical Practice.International journal of molecular sciences · 2023Review
- Natural Sirtuin1 Activators and Atherosclerosis: an Overview.Current atherosclerosis reports · 2023Review
- Therapeutic Role and Potential Mechanism of Resveratrol in Atherosclerosis: TLR4/NF-Mediators of inflammation · 2023Article
- Natural compounds from botanical drugs targeting mTOR signaling pathway as promising therapeutics for atherosclerosis: A review.Frontiers in pharmacology · 2023Review
- Network Pharmacology and Molecular Docking Study on the Multi-Target Mechanisms ofPlants (Basel, Switzerland) · 2022Article
- Natural products of traditional Chinese medicine treat atherosclerosis by regulating inflammatory and oxidative stress pathways.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis is a cardiovascular disease, which is characterized by the interaction between carbohydrates, lipids, cells and various other molecules and genetic factors. Previous studies have demonstrated that resveratrol (RV) served protective roles in numerous types of human disease by regulating different signaling pathways. The aim of the present study was to investigate the therapeutic effects of RV and analyze the potential RV-mediated mechanism in umbilical vein endothelial cells (UVECS) in atherosclerosis model mice. Reverse transcription-quantitative PCR, western blotting and immunohistochemistry were used to analyze the therapeutic effects of RV both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.